Mantle Cell Lymphoma Market to Grow with a CAGR of 6.89% through 2028
Rising investments and clinical trial expansion are
expected to drive the Global Mantle Cell Lymphoma Market growth in the forecast
period, 2024-2028.
According to TechSci Research report, “Mantle Cell
Lymphoma Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Mantle Cell Lymphoma Market
stood at USD 2.23 billion in 2022 and is anticipated to grow with a CAGR of 6.89%
in the forecast period, 2024-2028. The global mantle cell lymphoma market is
undergoing a significant transformation, fueled by advancements in targeted
therapies, immunotherapies, enhanced disease understanding, and increased
awareness. One of the most significant drivers of the global MCL market is the
development of targeted therapies specifically designed to combat this
aggressive lymphoma. Traditional treatments, such as chemotherapy and stem cell
transplantation, have limited long-term effectiveness and often come with
substantial side effects. However, targeted therapies, such as Bruton's
tyrosine kinase (BTK) inhibitors and phosphoinositide 3-kinase (PI3K)
inhibitors, have emerged as game-changers in MCL treatment. BTK inhibitors,
like ibrutinib, have shown remarkable efficacy in MCL patients by disrupting
signaling pathways crucial for cancer cell survival. These drugs have not only
extended progression-free survival but have also improved the overall quality
of life for patients, leading to increased adoption and market growth.
Immunotherapies, particularly chimeric antigen
receptor T-cell therapy (CAR-T), have gained significant traction in the MCL
market. CAR-T therapy involves modifying a patient's own T-cells to target
cancer cells with precision. This approach has shown impressive results in
clinical trials, demonstrating durable remissions in some MCL patients who had
exhausted other treatment options. The success of CAR-T therapy in MCL has
fueled research into further enhancing its effectiveness and minimizing side
effects. As these therapies progress, they are expected to become increasingly
prominent in the MCL treatment landscape. Advancements in genomics and a deeper
understanding of the underlying biology of mantle cell lymphoma have allowed
for the development of more tailored treatment strategies. Biomarker
identification and genetic profiling have enabled oncologists to select the
most appropriate therapy for individual patients, optimizing treatment
outcomes. This personalized medicine approach not only improves patient
responses but also minimizes unnecessary exposure to ineffective treatments,
reducing treatment-related side effects and healthcare costs. While MCL remains
a relatively rare lymphoma subtype, the global prevalence of the disease is
gradually increasing. This growing patient population has spurred greater
awareness among healthcare professionals and the public alike. Improved
understanding of MCL symptoms, diagnostic methods, and available treatments has
led to earlier detection and intervention, ultimately enhancing patient
outcomes.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Mantle
Cell Lymphoma Market.”
The global MCL market is witnessing a surge in
clinical trials focused on novel therapies and treatment combinations.
Pharmaceutical companies and research institutions are collaborating to test
new drugs, therapeutic regimens, and innovative treatment approaches. These
trials not only provide hope for patients with refractory or relapsed MCL but
also contribute valuable data to the scientific community, further advancing
our understanding of the disease. The mantle cell lymphoma market has become an
attractive space for pharmaceutical companies and investors due to the
promising results of targeted therapies and immunotherapies. This heightened
interest has led to increased investments in research and development,
accelerating the pace of drug discovery and innovation. These investments have
also facilitated the expansion of manufacturing capabilities to meet the
growing demand for MCL therapies.
The Global Mantle Cell Lymphoma Market is segmented
into Diagnosis, Treatment, End User, regional distribution, and company.
Based on the Treatment, the therapy segment emerged as
the dominant segment in the global market for Global Mantle Cell Lymphoma
Market in 2022. The primary reason for this dominance is the significant
advancements in MCL treatment options that have been achieved in recent years.
Targeted therapies, immunotherapies, and novel treatment regimens, such as
Bruton's tyrosine kinase (BTK) inhibitors, chimeric antigen receptor T-cell
(CAR-T) therapy, and combination therapies, have revolutionized the way MCL is
managed. These innovative
therapies have demonstrated remarkable efficacy in clinical trials, often
leading to extended progression-free survival and improved overall outcomes for
MCL patients. The rapid adoption of these therapies by healthcare providers,
coupled with increased investments and research, has contributed to the
dominance of the therapy segment in the MCL market.
Based on the Diagnosis, the laboratory exams segment
emerged as the dominant player in the global market for Global Mantle Cell
Lymphoma Market in 2022. Laboratory exams,
such as blood tests and immunohistochemistry, are less invasive compared to
procedures like bone marrow biopsy, making them more acceptable to patients. Also,
Laboratory exams are generally more cost-effective than imaging tests and
invasive procedures like bone marrow biopsy, making them accessible to a
broader population. Laboratory exams
can be used for ongoing monitoring of disease progression and treatment
response, allowing healthcare providers to make necessary adjustments to the
treatment plan. Laboratory facilities for blood tests and immunohistochemistry
are widely available in healthcare settings, ensuring accessibility for
patients worldwide.
Based on the By End User, the Hospitals & Clinics segment
emerged as the dominant player in the global market for Global Mantle Cell
Lymphoma Market in 2022. Hospitals and clinics are well-equipped to provide
specialized care for cancer patients, including those with MCL. They have
access to state-of-the-art diagnostic equipment and treatment facilities,
ensuring accurate diagnosis and the delivery of advanced therapies. These
healthcare facilities often have multidisciplinary teams of oncologists,
hematologists, pathologists, and radiologists who collaborate to provide
comprehensive care. This approach is vital in managing the complexity of MCL.
North America emerged as the dominant player in the
global Mantle Cell Lymphoma Market in
2022, holding the largest market share. North America boasts a robust and
technologically advanced healthcare infrastructure, providing a conducive
environment for the development and adoption of cutting-edge MCL treatments. The region is a hub for pharmaceutical and
biotechnology companies, with substantial investments in research and
development. This has led to the rapid development of novel therapies and
clinical trials in the MCL market.
Major companies operating in Global Mantle Cell
Lymphoma Market are:
- Kite Pharma, Inc. (Gilead Sciences,
Inc.)
- F. Hoffman La Roche Ltd
- Abbvie, Inc.
- Celgene Corporation
- Eli Lilly and Company
- Amgen, Inc.
- Takeda Pharmaceutical Co. Ltd
- AstraZeneca Plc
- Johnson and Johnson
- BeiGene GmBH
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“Advancements in
targeted therapies and immunotherapies have revolutionized the treatment
landscape for MCL, offering more effective and less toxic options.
Additionally, the growing prevalence of MCL, coupled with increased awareness
and early diagnosis, is expected to expand the patient pool, driving demand for
innovative treatments. Moreover, the expansion of clinical trials and research
initiatives focused on MCL is likely to yield promising results, leading to the
development of novel therapies and treatment combinations. The rise in investments
from both pharmaceutical companies and public funding sources is fueling
innovation and supporting the accessibility of these treatments. Furthermore,
favorable regulatory environments, expedited approvals, and the active
involvement of patient advocacy groups are expected to further accelerate the
introduction of new therapies into the market.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Mantle Cell Lymphoma Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Statins,
Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, MTP Inhibitors, ANGPTL3
Inhibitors), By Route of Administration (Oral, Parenteral, Nasal), By
Technology (CRISPR-Cas9, RNA Interference, Nanoparticle-Based Therapies), By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies) By Region and Competition”, has evaluated the future growth potential of Global
Mantle Cell Lymphoma Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Mantle
Cell Lymphoma Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com